Negative regulation of G0 to G1 transition

Across TCGA cell cohorts, RNA activity of the Negative regulation of G0 to G1 transition pathway is significantly associated with the drug response of multiple features, with the BLOOD_Lymphoma cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Entospletinib, rTRAIL, and Docetaxel, each associated with the pathway in up to 2 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Entospletinib grouped by Negative regulation of G0 to G1 transition-low versus -high activity in BLOOD_Lymphoma.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Lymphoma	Entospletinib →	-0.479	-0.154	.017	.031	2	1
LUNG_SCLC	rTRAIL →	+0.369	+2.149	.034	.005	1	2
LUNG_SCLC	Docetaxel →	+0.810	+2.149	.037	.005	1	1
LUNG_SCLC	CI-1040 →	+0.820	+2.149	.021	.005	1	1
LUNG_SCLC	Lestaurtinib →	+0.970	+2.149	.044	.005	1	1
LUNG_SCLC	Wee1 Inhibitor →	+0.304	+2.149	.031	.005	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Entospletinib by Negative regulation of G0 to G1 transition activity — BLOOD_Lymphoma

Explore this box plot interactively →